Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $2.02 USD
Change Today -0.09 / -4.27%
Volume 392.1K
SQNM On Other Exchanges
As of 8:10 PM 10/12/15 All times are local (Market data is delayed by at least 15 minutes).

sequenom inc (SQNM) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/5/15 - $4.80
52 Week Low
09/29/15 - $1.53
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SEQUENOM INC (SQNM)

sequenom inc (SQNM) Related Businessweek News

View More BusinessWeek News

sequenom inc (SQNM) Details

Sequenom, Inc., a life sciences company, develops and commercializes molecular diagnostics testing services for the women's health and oncology markets in the United States and internationally. The company provides molecular based laboratory developed tests (LDTs) comprising MaterniT21 PLUS LDT, a noninvasive prenatal test (NIPT) to detect fetal chromosomal abnormalities; HerediT CF LDT, a carrier screen test to identify individuals with cystic fibrosis or genetic mutations; SensiGene fetal Rhesus D (RhD) LDT, a NIPT to determine the presence or absence of RhD factor by direct detection of the fetal RhD genotype in RhD negative mothers from a maternal blood sample; and VisibiliT LDT, a NIPT to detect fetal chromosomal abnormalities by determining the relative amount of chromosomal material present in circulating cell-free DNA in a maternal blood sample. It also offers a microarray test that uses fetal samples obtained by amniocentesis or chorionic villus sampling under the NextView brand; additional carrier screening tests for Ashkenazi Jewish disorders, spinal muscular atrophy, and fragile X syndrome under the HerediT brand; and RetnaGene age-related macular degeneration (AMD) test to predict the risk of a patient with dry or early stage AMD progressing to wet or advanced choroidal neovascular disease within 2, 5, and 10 years. The company serves physicians and client laboratories. It has collaboration with the Seoul National University Hospital. The company was founded in 1994 and is headquartered in San Diego, California.

448 Employees
Last Reported Date: 03/10/15
Founded in 1994

sequenom inc (SQNM) Top Compensated Officers

Interim Chief Executive Officer, Interim Pres...
Total Annual Compensation: $407.6K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $343.9K
Senior Vice President of Corporate Governance...
Total Annual Compensation: $300.2K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $111.0K
Compensation as of Fiscal Year 2014.

sequenom inc (SQNM) Key Developments

Sequenom Enters Clinical Collaboration with Seoul National University Hospital

Sequenom Inc. announced that it has entered into a clinical collaboration with Seoul National University Hospital. SNUH and Sequenom will collaborate to profile circulating cell-free tumor DNA in blood in a series of research studies targeting several hundred patients across a wide variety of cancer types. Sequenom is currently developing a Research Use Only (RUO) assay with an initial focus on the detection and molecular profiling of late stage non-hematologic malignancies in settings where tissue biopsies are not available or are too risky to obtain. The assay will cover a breadth of cancer types by analyzing over 100 cancer-related genes that are included in professional society guidelines, linked to targeted therapies currently in clinical trials, or part of well-documented cancer pathways. This clinical research study will aim to enroll several hundred patients across 10 different cancer types.

Sequenom, Inc. Announces Management Changes

Sequenom Inc. announced the appointment of Dirk van den Boom, Ph.D. to the position of interim President and Chief Executive Officer. Dr. van den Boom succeeds William J. Welch following his resignation from that role, and as a director, to pursue other interests. In addition, Dr. van den Boom will continue to serve as the company’s Chief Scientific and Strategy Officer. Prior to his appointment as Interim President and CEO, Dr. van den Boom served as Chief Scientific and Strategy Officer since June 2014, and before that as Executive Vice President, Research and Development and Chief Technology Officer beginning in December 2012. Dr. van den Boom joined the company in 1998 at the company's Hamburg office, subsequently serving in various management roles of increasing responsibility.

Sequenom Inc. Presents at Morgan Stanley Global Healthcare Conference - New York, Sep-16-2015 03:40 PM

Sequenom Inc. Presents at Morgan Stanley Global Healthcare Conference - New York, Sep-16-2015 03:40 PM. Venue: The Grand Hyatt New York, 109 East 42nd Street, New York, New York, United States. Speakers: Carolyn D. Beaver, Chief Financial Officer and Senior Vice President, William J. Welch, Chief Executive Officer, President and Director.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SQNM:US $2.02 USD -0.09

SQNM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biotage AB kr19.00 SEK +0.50
Enzo Biochem Inc $3.73 USD -0.02
NanoString Technologies Inc $15.33 USD -0.22
Natera Inc $9.20 USD -0.28
Transgenomic Inc $0.95 USD +0.0281
View Industry Companies

Industry Analysis


Industry Average

Valuation SQNM Industry Range
Price/Earnings 15.6x
Price/Sales 1.7x
Price/Book NM Not Meaningful
Price/Cash Flow 14.3x
TEV/Sales 0.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SEQUENOM INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at